doi: 10.1016/j.jaad.2022.07.047.
Epub 2022 Aug 4.
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study
Affiliations
- PMID: 35934210
- DOI: 10.1016/j.jaad.2022.07.047
Item in Clipboard
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study
J Am Acad Dermatol.
2022 Dec.
No abstract available
Keywords: Janus kinase; acne inversa; efficacy; hidradenitis suppurativa; safety; upadacitinib.
Conflict of interest statement
Conflicts of interest Dr Frew has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie, Azora, Novartis, and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, and Azora, and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB, and La Roche Posay.
Similar articles
-
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study.J Am Acad Dermatol. 2025 Jun;92(6):1252-1260. doi: 10.1016/j.jaad.2024.12.046. Epub 2025 Feb 4. J Am Acad Dermatol. 2025. PMID: 39909350 Clinical Trial.
-
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500. J Drugs Dermatol. 2023. PMID: 38051858
-
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.Medicina (Kaunas). 2023 Apr 20;59(4):801. doi: 10.3390/medicina59040801. Medicina (Kaunas). 2023. PMID: 37109759 Free PMC article. Review.
-
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.J Am Acad Dermatol. 2024 May;90(5):1031-1034. doi: 10.1016/j.jaad.2024.01.004. Epub 2024 Jan 9. J Am Acad Dermatol. 2024. PMID: 38199282 No abstract available.
-
Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.J Am Acad Dermatol. 2024 Dec;91(6S):S31-S36. doi: 10.1016/j.jaad.2024.09.014. J Am Acad Dermatol. 2024. PMID: 39626997 Review.
Cited by
-
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19. J Eur Acad Dermatol Venereol. 2025. PMID: 39699926 Free PMC article.
-
Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.Adv Healthc Mater. 2024 May;13(12):e2303256. doi: 10.1002/adhm.202303256. Epub 2024 Jan 26. Adv Healthc Mater. 2024. PMID: 38207170 Free PMC article.
-
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4. Dermatol Ther (Heidelb). 2023. PMID: 37402031 Free PMC article. Review.
-
Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.JAAD Case Rep. 2024 Dec 16;56:74-76. doi: 10.1016/j.jdcr.2024.12.008. eCollection 2025 Feb. JAAD Case Rep. 2024. PMID: 39866333 Free PMC article. No abstract available.
-
Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib.Cureus. 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan. Cureus. 2024. PMID: 38361718 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
